These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

179 related articles for article (PubMed ID: 227340)

  • 1. Fluphenazine and social therapy in the aftercare of schizophrenic patients. Relapse analyses of a two-year controlled study of fluphenazine decanoate and fluphenazine hydrochloride.
    Hogarty GE; Schooler NR; Ulrich R; Mussare F; Ferro P; Herron E
    Arch Gen Psychiatry; 1979 Nov; 36(12):1283-94. PubMed ID: 227340
    [TBL] [Abstract][Full Text] [Related]  

  • 2. Fluphenazine decanoate, fluphenazine hydrochloride given orally, and placebo in remitted schizophrenics. I. Relapse rates after one year.
    Rifkin A; Quitkin F; Rabiner CJ; Klein DF
    Arch Gen Psychiatry; 1977 Jan; 34(1):43-7. PubMed ID: 189724
    [TBL] [Abstract][Full Text] [Related]  

  • 3. Prevention of relapse in schizophrenia. An evaluation of fluphenazine decanoate.
    Schooler NR; Levine J; Severe JB; Brauzer B; DiMascio A; Klerman GL; Tuason VB
    Arch Gen Psychiatry; 1980 Jan; 37(1):16-24. PubMed ID: 7352836
    [TBL] [Abstract][Full Text] [Related]  

  • 4. The contribution of fluphenazine enanthate and decanoate in the prevention of readmission of schizophrenic patients.
    Denham J; Adamson L
    Acta Psychiatr Scand; 1971; 47(4):420-30. PubMed ID: 4336483
    [No Abstract]   [Full Text] [Related]  

  • 5. A depot neuroleptic withdrawal study. A controlled study of the clinical effects of the withdrawal of depot fluphenazine decanoate and depot flupenthixol decanoate in chronic schizophrenic patients.
    Wistedt B
    Acta Psychiatr Scand; 1981 Jul; 64(1):65-84. PubMed ID: 7032224
    [TBL] [Abstract][Full Text] [Related]  

  • 6. Fluphenazine decanoate, oral fluphenazine, and placebo in treatment of remitted schizophrenics. II. Rating scale data.
    Rifkin A; Quitkin F; Klein DF
    Arch Gen Psychiatry; 1977 Oct; 34(10):1215-9. PubMed ID: 199129
    [TBL] [Abstract][Full Text] [Related]  

  • 7. Costs and benefits of two doses of fluphenazine.
    Marder SR; Van Putten T; Mintz J; McKenzie J; Lebell M; Faltico G; May PR
    Arch Gen Psychiatry; 1984 Nov; 41(11):1025-9. PubMed ID: 6437365
    [TBL] [Abstract][Full Text] [Related]  

  • 8. Depot fluphenazine decanoate and enanthate for schizophrenia.
    David A; Adams CE; Eisenbruch M; Quraishi S; Rathbone J
    Cochrane Database Syst Rev; 2005 Jan; (1):CD000307. PubMed ID: 15674872
    [TBL] [Abstract][Full Text] [Related]  

  • 9. Fluphenazine vs placebo in patients with remitted, acute first-episode schizophrenia.
    Kane JM; Rifkin A; Quitkin F; Nayak D; Ramos-Lorenzi J
    Arch Gen Psychiatry; 1982 Jan; 39(1):70-3. PubMed ID: 6275811
    [TBL] [Abstract][Full Text] [Related]  

  • 10. Fluphenazine vs placebo supplementation for prodromal signs of relapse in schizophrenia.
    Marder SR; Wirshing WC; Van Putten T; Mintz J; McKenzie J; Johnston-Cronk K; Lebell M; Liberman RP
    Arch Gen Psychiatry; 1994 Apr; 51(4):280-7. PubMed ID: 8161288
    [TBL] [Abstract][Full Text] [Related]  

  • 11. Long-acting phenothiazines in the prevention of relapse of schizophrenic patients.
    Denham J; Adamson L
    Can Psychiatr Assoc J; 1973 Jun; 18(3):235-7. PubMed ID: 4352360
    [No Abstract]   [Full Text] [Related]  

  • 12. Double-blind placebo substitution: withdrawal of fluphenazine decanoate in schizophrenic patients.
    Odejide OA; Aderounmu AF
    J Clin Psychiatry; 1982 May; 43(5):195-6. PubMed ID: 7076630
    [TBL] [Abstract][Full Text] [Related]  

  • 13. Plasma levels of fluphenazine in patients receiving fluphenazine decanoate. Relationship to clinical response.
    Marder SR; Midha KK; Van Putten T; Aravagiri M; Hawes EM; Hubbard JW; McKay G; Mintz J
    Br J Psychiatry; 1991 May; 158():658-65. PubMed ID: 1860020
    [TBL] [Abstract][Full Text] [Related]  

  • 14. Low dose fluphenazine decanoate in maintenance treatment of schizophrenia.
    Kane JM; Rifkin A; Quitkin F; Nayak D; Saraf K; Ramos-Lorenzi JR; Klein DF; Sachar EJ
    Psychiatry Res; 1979 Dec; 1(3):341-8. PubMed ID: 233160
    [TBL] [Abstract][Full Text] [Related]  

  • 15. A double-blind dose-reduction trial of fluphenazine decanoate for chronic, unstable schizophrenic patients.
    Inderbitzin LB; Lewine RR; Scheller-Gilkey G; Swofford CD; Egan GJ; Gloersen BA; Vidanagama BP; Waternaux C
    Am J Psychiatry; 1994 Dec; 151(12):1753-9. PubMed ID: 7977881
    [TBL] [Abstract][Full Text] [Related]  

  • 16. The use of depot neuroleptics: clinical experience in the United States.
    Kane JM
    J Clin Psychiatry; 1984 May; 45(5 Pt 2):5-12. PubMed ID: 6370987
    [TBL] [Abstract][Full Text] [Related]  

  • 17. Discontinuation of oral and depot fluphenazine in schizophrenic patients after one year of continuous medication: a controlled study.
    Levine J; Schooler NR; Severe J; Escobar J; Gelenberg A; Mandel M; Sovner R; Steinbook R
    Adv Biochem Psychopharmacol; 1980; 24():483-93. PubMed ID: 6996445
    [No Abstract]   [Full Text] [Related]  

  • 18. Very high dose fluphenazine decanoate: a controlled trial in chronic schizophrenia.
    McClelland HA; Farquharson RG; Leyburn P; Furness JA; Schiff AA
    Arch Gen Psychiatry; 1976 Dec; 33(12):1435-9. PubMed ID: 11760
    [TBL] [Abstract][Full Text] [Related]  

  • 19. Two-year trial of maintenance neuroleptic dose reduction in schizophrenic out-patients: predictors of relapse.
    Heresco-Levy U; Greenberg D; Lerer B; Dasberg H; Brown WA
    Isr J Psychiatry Relat Sci; 1995; 32(4):268-75. PubMed ID: 8641856
    [TBL] [Abstract][Full Text] [Related]  

  • 20. Fluphenazine decanoate and fluphenazine enanthate in the out-patient management of chronic schizophrenia.
    MacCrimmon DJ; Saxena B; Foley P; Grof P
    Neuropsychobiology; 1978; 4(6):360-5. PubMed ID: 692838
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 9.